ǰÑÔ
ÉöСÇò¼²²¡(glomerular diseases)ÊDz¡Òò¡¢·¢²¡»úÖÆ¡¢ÁÙ´²ÌåÏÖ¡¢²¡Àí¸Ä±ä¡¢²¡³ÌºÍÔ¤ºó²»¾¡ÏàͬµÄÖ÷ÒªÀÛ¼°Ë«ÉöÉöСÇòµÄÒ»×é¼²²¡£¬¿É·ÖΪԷ¢ÐÔ¡¢¼Ì·¢ÐÔºÍÒÅ´«ÐÔ¡£´ó¶¼ÉöСÇòÉöÑ×ÊÇÃâÒ߽鵼ÐÔÑ×Ö¢¼²²¡¡£Ò»Ñùƽ³£ÒÔΪ£¬ÃâÒß»úÖÆÊÇÉöСÇò²¡µÄʼ·¢»úÖÆ£¬ÉöСÇò¼²²¡¶¯ÎïÄ£×ÓÔÚ̽ÌÖ·¢²¡»úÖÆ¡¢²¡ÀíÀú³ÌÒÔ¼°ÁÙ´²ÖÎÁƵȷ½ÃæÊ©Õ¹Ö÷Òª×÷Óᣱ¾½ÚÖ÷ÒªÏÈÈÝÁËϵĤÔöÖ³ÐÔÉöСÇòÉöÑס¢Thy1ϵĤÔöÉúÐÔÉöÑס¢Ï¸Ð¡²¡±äÐÍÉö²¡¡¢IgAÉö²¡ÒÔ¼°ÉöСÇòÓ²»¯ÐÔÉö²¡¶¯ÎïÄ£×ӵĽ¨ÉèÒªÁìºÍÌØµã¡£
ϸС²¡±äÐÍÉö²¡(minimal change nepbrosis,MCN)ÓÖ³ÆÎªÀàÖ¬ÐÔÉö²¡(lipoid nephrosis)£¬¹â¾µÏÂÉöСÇò»ù±¾Õý³££¬µç¾µÏÂÉöСÇòÉÏÆ¤×ãͻϸ°ûµÄÍ»ÆðÈںϡ¢ÏûÊÅ£¬ÎÞÏÔ×ÅϵĤϸ°ûÔöÉú¡¢»ùÖÊÔö¿íºÍÃâÒßÇòÂѰ׳Á»ý¡£MCN¿É·ÖΪԷ¢ÐԺͼ̷¢ÐÔÁ½À࣬Է¢ÐÔ²¡ÒòδÃ÷£¬ÁÙ´²ÌåÏÖΪÉö²¡×ÛºÏÕ÷£º´ó×ÚÂѰ×Äò¡¢µÍÂѰ×Ѫ֢¡¢Ë®Öס¢¸ß֬Ѫ֢µÈ¡£MCNÊǶùͯ×î³£¼ûµÄÒ»ÖÖÉöСÇò¼²²¡¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
°¢Èá±ÈÐÇ(aclarubicin)¡¢¶àÈá±ÈÐÇ¡¢àÑßÊÃ¹ËØºÍÈáºìÃ¹ËØ¾ù¿ÉÓÕµ¼½¨ÉèMCN¡£ÆäÖа¢Èá±ÈÐÇ»ò¶àÈá±ÈÐǵȺ¬õ«µÄÝì»·¿¹ÉúËØ£¬ÔÚÉöÔàÄڿɱ»´úл»¹ÔΪ°ëõ«ÐÍ×ÔÓÉ»ù£¬²¢ÓëÑõ·´Ó¦±¬·¢ÑÄÐÔÑõ£¬¼Ì¶øÓÕ·¢ÉöСÇòÉÏÆ¤Ï¸°ûÖ¬ÖʹýÑõ»¯·´Ó¦£¬¸Ä±äÉöСÇòÉÏÆ¤Ï¸°ûµÄÌÇÂѰ״úл£¬ÆÆËðÉöСÇòÂ˹ýĤµÄ½á¹¹ºÍ¹¦Ð§£¬µ¼ÖÂĤÂ˹ýÆÁÕϵÄÑ¡ÔñÐÔת±ä¶øÒýÆðÂѰ×Äò£¬ÓÕ·¢µä·¶µÄMCNÄ£×Ó¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
1.ʵÑéÀú³Ì ÐÛÐÔSprague Dawley´óÊó£¨ÌåÖØ180~220g)¾Í¨Ë×ËÇÁÏ˳ӦÐÔËÇÑø1Öܺó£¬ÄòÂѰײⶨΪÒõÐÔÕßÓÃÓÚºóÐøÊµÑé¡£ÔìÄ£×é´óÊó·ÖÁ½´Î¾Î²¾²Âö×¢Éä°¢Èá±ÈÐÇ£»µÚ1´Î×¢Éä4mg/kg£¬¾àÀë1ÖÜ£¬ÔÙ³ö3mg/kg¡£´ÓµÚ1´Î¸øÒ©Æð£¬ÓÚµÚ1¡¢2¡¢3¡¢4ÖÜÄ©ÁôÈ¡24СʱÄò£¬Æä¼ä¸øÓè¸ßÂѰ×Òûʳ¡£µÚ4ÖÜÄ©Õý·¨¶¯ÎȡѪ±ê±¾ºÍÉöÔà×öÏìÓ¦¼ì²é¡£
2.Ö¸±ê¼ì²â ²â¶¨ÄòÂѰ׶¨Á¿¡¢Ñª½¬ÇåÂѰס¢×ÜÂѰס¢ÑªÇ嵨¹Ì´¼¡¢ÑªCr£¬ÉöÔಡÀíÇÐÆ¬¾ÙÐÐH&EºÍPASȾɫ£¬×îºóʹÓÃ͸Éäµç¾µÊÓ²ìÉöÔàµÄ³¬Î¢½á¹¹¡£
¡¾Ä£×ÓÌØµã¡¿£º
1.´óÊóµÚ1´Î¸øÒ©ºóÄòÂѰ×ÓÚµÚ7Ìì×îÏÈÉÏÉý£¬µÚ28Ìì¿É´ï80mg/24h£¬Í¬Ê±°éÓÐÏÔ×ŵÍÂѰ×Ѫ֢¡¢¸ßµ¨¹Ì´¼ÑªÖ¢¡£
2.¹â¾µ¿É¼ûÉöÔಡÀíÎÞÏÔÖø×ª±ä£¬È»¶øÍ¸Éäµç¾µ¿É¼ûÉöÔà×éÖ¯ÄÚÉöСÇòÉÏÆ¤Ï¸°û×ãÍ»ÆÕ±éÈںϣ¬»ùµ×ĤÔöºñ¡£
3.ÔìÄ£ÀÖ³ÉÂʽϸߣ¬¸¹ÐºË®Æ½½ÏÇᣬδ¼û´óÊóéæÃü¡£
4.²¡ÀíÄ£×Ó¸ü¿¿½üÁÙ´²²¡ÀíÊӲ죬ÇкÏMCNµÄ²¡Àí¸Ä±ä¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
Á½´Î×¢Éä°¢Èá±ÈÐÇÓÕµ¼Ëù½¨ÉèµÄ´óÊóÉö²¡Ä£×ÓÀû±ã¡¢¿É¿¿£¬ÓÅÓÚÆäËûÒ©ÎïÓÕµ¼Ä£×Ó£¬ÓëÈËÀàMCN²¡±ä¾ßÓнϺõÄÏàËÆÐÔ¡£È»¶ø£¬Ò©ÎïÓÕµ¼µÄÄ£×ÓÔÚ·¢²¡»úÖÆ¡¢ÁÙ´²ÌåÏֺͶÔÖÎÁƵķ´Ó¦ÉϾùÓëÈËÀàMCN±£´æÒ»Ð©²î±ð¡£¸ÃÄ£×ÓÄܹ»ÎªÌ½Ë÷Ô·¢ÐÔÉö²¡µÄ·¢²¡»úÖÆ¼°Ò©Îï·ÀÖÎÑо¿ÌṩÓÅÒìµÄʵÑé»ù´¡£¬ÌØÊâÊÇÔÚ¶ùͯÉö²¡µÄÑо¿ÖÐÓÈΪÖ÷Òª¡£
²Î¿¼ÎÄÏ×£º
1.ÌÀÓ±£¬Â¦Ì½Ææ£¬³É²ÊÁª£¬µÈʵÑéÐÔIgAÉö²¡Ä£×ÓµÄˢУ®ÖÐɽ´óѧѧ±¨£¨Ò½Ñ§¿ÆÑ§°æ£©£¬2006,27 (2): 184-187
2.Î⺺Àû£¬Ëïΰ£®°¢Èá±ÈÐǽ¨ÉèÉö²¡Ä£×ӵįÀ¼Û£®ÖйúÖÐÒ½¼±Ö¢£¬2010,19 (2):290-191
3.ÕÅÀö·Ò£¬»ÆÎÄÕþ£¬ÖìС馣¬µÈ£®°¢Ã¹ËØÉö²¡ÉöСÇòÓ²»¯¶¯ÎïÄ£×ÓµÄÑо¿. ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2005,6 (4):195-199
4.Õſ˷ǣ¬ÕÅÁÁ£¬ÎâÐÛ·É£¬µÈ£®´óÊó¿¹Thy1ϵĤÔöÉúÐÔÉöСÇòÉöÑ×Ä£×Ó·¢²¡»úÖÆÌ½ÌÖ£®ËÄ´¨´óѧѧ±¨£¨Ò½Ñ§°æ£©£¬ 2004,35 (2): 188-190
5.³Â¹ãƽ£¬¹ù¹§ÒÀ£¬ÕÅÔ¶𣬵ȣ®´óÊóThy1¿¹ÑªÇåÖÆ±¸¼°ÏµÄ¤ÔöÉúÐÔÉöÑ×Ä£×ӵĽ¨É裮ÁÙ´²ÓëʵÑ鲡ÀíѧÔÓÖ¾£¬1996, 12 (3):241-243
6.»ÆÊ¤£¬ËïÁÖ£¬Ò¶Èθߣ¬µÈ£®Á½ÖÖϵĤÔöÖ³ÐÔÉöÑ×´óÊóÄ£×ӵĽ¨Éè½ÏÁ¿£®ÖйúʵÑ鶯Îïѧ±¨£¬2002, 10 (4): 236-238
7.Marquina R, Dfez MA,López-Hoyos M,el al. Inhibition of B cell death causes the development of an lgA nephropathy in(New Zealand white x C578L/6)F(1)-bel-2 transgenic mice. J lmmunol,2004,172(11):7177-7185
8.Zhang Z, Kundu GC, Yuan CJ, el al. Severe fibroneclindeposit renal glomerular disease in mice lacking uteroglobin. Science, 1997,276(5317): 1408-1412